MoonLake Immunotherapeutics (MLTX) FinancialsMLTXMoonLake Immunotherapeutics

Evaluating the bottom line, MoonLake Immunotherapeutics maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -67.44%, provide a clear picture of how effectively MLTX converts its operational activities into shareholder value.

In the context of the broader market, MLTX competes directly with industry leaders such as RIGL and ALMS. With a market capitalization of $908.94M, it holds a leading position in the sector. When comparing efficiency, MLTX's gross margin of N/A stands against RIGL's 89.17% and ALMS's 100.00%. Such benchmarking helps identify whether MoonLake Immunotherapeutics is trading at a premium or discount relative to its financial performance.

MoonLake reported a narrower Q2 loss of $0.84 per share, better than the expected loss of $0.93, and has a forward P/E ratio of 0, indicating no current earnings, which is typical for pre-revenue biotech firms.